Genetic Hallmarks of Patients With Congenital Portosystemic Shunts and Portopulmonary Hypertension

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age1-99
SponsorProf. Valérie Mc Lin

About this trial

Congenital portosystemic shunt (CPSS) are rare vascular malformations causing blood from the intestines to bypass the liver and directly flow into body's general circulation. Such liver bypass can cause several health problems, one of the most severe being portopulmonary hypertension (PoPH).

The goal of this study is to identify pathogenic and potentially pathogenic genetic variants in patients who have both CPSS and PoPH. Future research will assess the contribution of these genetic variants to the development of PoPH.

The long-term goal is to use genetic information to identify patients with congenital portosystemic shunts (CPSS) or chronic liver disease who are at risk of developing PoPH to offer anticipatory management.

Children and adult patients with both CPSS and PoPH, as well as their close relatives (patient's parents and siblings) can take part in the study. Genetic variations within each family will be studied.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Patient is a participant to the IRCPSS with history of PoPH

Trios composed of CPSS PoPH patients and their parents (trios are mandatory)

Brother/sister of an enrolled patient

Trios accept to provide biological samples (blood), sign the inform consent.

Disqualifiers

Trio condition is not met.

No genuine parent-offspring trios (check for medically assisted procreation with donors, and adoption)

For siblings, half-brothers or half-sisters are excluded, as well as adopted children, or children issued from medically assisted procreation with donors.

Secondary portosystemic shunts

Trial population

Patient participant in the IRCPSS, with history of CPSS and PoPH ; both parents of the patient participants; possibly patient siblings.

Trial design

Design model

Family-based

Time perspective

Other

Treatments tested in this trial

  • targeted gene panels analysis

    Genetic

    The following gene panels will be analyzed : pulmonary arterial hypertension ; hereditary hemorrhagic telangiectasia ; congenital heart disease and potentially pathogenic variants in genes previously associated with PoPH in cirrhosis cohort.

  • whole genome analysis

    Genetic

    Family-based identification of dominant or recessive potentially pathogenic variants.

Treatment groups

120 Participants
are divided into 1 treatment group
Group A: 30 families2 interventions

Trial outcomes

Primary outcomes

1

List of variants from targeted analysis of selected gene panels

presence/absence of pathogenic variants in known genes (pulmonary arterial hypertension ; hereditary hemorrhagic telangiectasia ; congenital heart disease) and potentially pathogenic variants in genes previously associated with PoPH in cirrhosis cohort.

Time frame
From February 2026 to February 2029
2

List of variants from whole genome analysis

variants identified using family based search for dominant or recessive potentially pathogenic variants

Time frame
Fron February 2026 to August 2029

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Prof. Valérie Mc Lin

Lead sponsor

University Hospital, Geneva

Sponsor institution

This trial is not recruiting at the moment. You can still explore other options: